22 August 2024 in ERJ Open Research
Introduction: Progressive pulmonary fibrosis (PPF) corresponds to any fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) that presents clinical, physiological and/or radiological evidence of disease progression similar to IPF. Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of pulmonary fibrosis and are associated with disease progression and reduced survival in IPF and other fibrotic ILDs. This study aimed to investigate the role of serum levels of MMP-1 and MMP-7 in patients with fibrotic non-IPF ILD as possible biomarkers of patients at risk of developing PPF.Methods: Newly diagnosed patients with fibrotic non-IPF ILD were included in this study. Serum levels of MMP-1 and MMP-7 were quantified at baseline and disease progression was monitored. PPF was defined according to the recent European Respiratory Society, American Thoracic Society, Japanese Respiratory Society and the Latin American Thoracic Society Clinical Practice Guidelines.Results: 79 patients with fibrotic non-IPF ILDs were included and classified as having PPF or non-PPF. Significantly higher levels of MMP-7, but not MMP-1, were detected in the PPF group (p=0.01). MMP-7 was independently associated with PPF (adjusted OR 1.263, 95% CI 1.029–1.551; p=0.026) after adjustment for sex, age and smoking history. A cut-off value of 3.53 ng·mL−1for serum MMP-7 levels had a sensitivity of 61% and a specificity of 74% for predicting PPF in non-IPF ILDs.Conclusions: In patients with fibrotic non-IPF ILDs, serum MMP-7 levels were significantly greater in the subgroup of patients meeting the PPF criteria at follow-up. This can be considered and further investigated as a possible biomarker to identify fibrotic ILD patients at risk of PPF.
2 August 2021 in Pulmonology
28 May 2024 in Archivos de Bronconeumología
18 October 2024 in Respiratory Medicine
22 December 2025 in Pulmonology
Background: The use of home mechanical ventilation (HMV) has been increasing worldwide, driven by widening of clinical applications and improved patient survival rates. In Portugal, recent data indicate an even faster growth, although national HMV recommendations have remained unchanged for 25 years. Research question: We aimed to provide an update in clinical practice guidelines for HMV in adults, applicable to the Portuguese context, grounded on the latest available evidence and experts' opinion. Study design and methods: A multidisciplinary panel with experience in HMV in the adult population was assembled. A comprehensive literature search was conducted during March 2023 regarding specific topics: equipment, ventilatory modes and interfaces, HMV initiation, follow-up and monitoring, disease specificities (neuromuscular diseases, obesity-hypoventilation syndrome, restrictive chest wall diseases; chronic obstructive pulmonary disease, and other diseases), home mechanical invasive ventilation, and palliative and end of life care. A 2-round Delphi process was conducted to establish consensus among panel members. A minimum agreement threshold of 80% was required. Results: Out of 88 recommendations initially included in the Delphi process, 61 were selected by consensus. Conclusion: Final recommendations grounded in the current level of evidence are outlined, and the key limitations and proposals for future research are discussed.
9 September 2023 in European Respiratory Journal
Introduction: Progressive pulmonary fibrosis (PPF) is defined as an Interstitial Lung Disease (ILD), other than Idiopathic Pulmonary Fibrosis (IPF), with clinical, physiological and/ or radiological evidence of disease progression resembling IPF behavior. The matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of lung fibrosis and MMP-1 and MMP-7 have been suggested as an IPF diagnostic biomarker. Aim and objectives: To investigate MMP-1 and MMP-7 in the identification of fibrotic non-IPF ILD patients at risk for PPF. Methods: We measured MMP-1 and MMP-7 serum levels in 79 fibrotic non-IPF ILDs patients: 35 Connective Tissue Disorder-ILD, 23 Fibrotic Hypersensitivity Pneumonitis, 13 Sarcoidosis, 6 Nonspecific Interstitial Pneumonia and 2 Unclassified Fibrotic ILD. PPF was defined according with the ATS/ERS/JRS/ALAT Clinical Practice Guideline. Results: The mean age was 62 years, 75.9% females. PPF criteria was met by 33 (41.7%) patients. MMP-7 (but not MMP-1) was significantly higher in the PPF group (p=0.01). Using the binary logistic regression model MMP-7 was independently associated with PPF (OR=1.263; 95% CI 1.029—1.551, p=0.026), remaining significant after adjusting for sex, age and smoking history; the cutoff of 3.526 ng/mL presented a sensitivity of 61% and a specificity of 74% for PPF. Conclusions: MMP-7 was significantly higher in the group of patients with PPF. This may be considered and further explored as a possible biomarker to identify those fibrotic ILDs patients at risk of PPF.